Fundamental Analysis of Novo Nordisk A/S - Growth / Value Index
NVO - Valuation Highlights
Valuation Analysis
Tsr Value Index - Excellent Score of 95.00
Undervalued - Price to Intrinsic Value of 0.0121
Price to Earning Ratio is 2.24 and EV to EBITDA is 1.86 suggesting company is undervalued.
Tremendous increasing in Book Value last 3 year
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 2.23 | 2.45 | -18.12 % | |
Price to Book | 1.81 | 1.72 | -26.62 % | 1.47 |
Price to Sales | 0.792 | 0.850 | -20.97 % | |
Enterprise Value to EBITDA Multiple | 1.85 | 2.70 | 18.19 % |
NVO - Profitability Highlights
Profitability Analysis
Earning Yield of 44.59 %
Tremendous increasing trend in Net Profit for last 3 year
Excellent Net Margin for last 3 years
Over the last 3 years, the company has achieved Incredible Return on Equity
Over the last 3 years, the company has achieved Incredible Return on Assets
Strong Return On Capital Employed of 42.16
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 81.29%
During the past twelve months, the company has given a strong Return On Asset of 25.20%
During the past twelve months, the company has given a strong Net Margin of 35.61%
All key Trailing Twelve Months Margin growing by 15 %
EBITDA is continuously increasing for last 3 Years
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 81.29 | 70.38 | -10.38 % | 15.77 |
Return On Asset | 25.20 | 21.68 | -18.52 % | 5.50 |
Net Profit Margin | 35.61 | 34.78 | -3.48 % | 34.48 |
Operating Profit Margin | 45.78 | 44.19 | 10.49 % | 43.52 |
EBITDA Margin | 46.72 | 41.92 | -13.79 % | 47.22 |
Highlights
Market Cap | 187325 M |
Enterprise Value | 269029 M |
Price/Book TTM | 1.81 |
Outstanding Share | 3368.56 M |
Float/ Outstanding Share | 94.64% |
Dividend Yield | 2.94 % |
Share Holding
Guru Numbers
Price/Graham No | 0.413 |
Peter Lynch Ratio | 9.96 |
Piotroski F Score | 6.00 |
Altman Z Score | 2.06 |
Sloan Ratio | 0.234 |
Peter Lynch Fair Value | 401.53 |
NVO - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 311938 M | 25.03 % | 1.58 % |
Gross Profit | 261870 M | 25.13 % | 1.82 % |
EBITDA | 145737 M | 7.79 % | 4.61 % |
Net Profit | 111068 M | 20.68 % | 8.72 % |
EPS | 24.99 | 22.13 % | NA |
NVO - Stability Highlights
Stability Analysis
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.679 | 222.01 % | 0.591 |
Cash Ratio | 0.121 | -32.13 % | |
Quick Ratio | 0.552 | -13.17 % | 0.564 |
Shareholders Equity | 30.80 | -9.09 % | |
Debt to EBITDA | 0.800 | 302.27 % |
Historical Valuation Ratios of Novo Nordisk A/S
Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Novo Nordisk A/S
Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Novo Nordisk A/S
Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Novo Nordisk A/S
Historical Solvency Ratios
Loading ...

Note : All Data Generated at the End of Trading Hours (EOD Data)